Based on the provided data and current market status (Sunday night), here's the analysis for GILD's price prediction for the next trading week:
Technical Analysis
- RSI (14) at 68.44 indicates approaching overbought territory but not yet extreme
- MACD shows positive momentum with MACD (2.65) above signal line (1.85)
- Price is trading above all major moving averages (SMA 5,10,20,60,200)
- Bollinger Bands show price near upper band (BBP at 0.81), suggesting strong momentum
Recent Price Action
- Current price: $104.08
- Last week's trading range: $103.92 - $106.69
- Volume has been moderate with average daily volume around 6.4M shares
Fundamental Catalysts
- Q4 2024 results exceeded expectations with adjusted EPS of $1.90 vs $1.70 consensus
- Strong HIV segment performance with 16% sales growth to $5.45B
- Potential launch of lenacapavir for HIV PrEP in Summer 2025
- Piper Sandler raised price target to $110 with Overweight rating
Price Targets for Next Week
- Support levels: $102.63 (Friday's close), $100.25 (Fibonacci pivot)
- Resistance levels: $104.89 (R1), $107.75 (R2)
Trading Recommendation
SELL with the following rationale:
- RSI approaching overbought levels
- Price near upper Bollinger Band suggesting potential pullback
- Recent insider selling activity with CFO selling 137,676 shares
- Multiple institutional investors reducing positions last quarter
Target entry for short positions: $104.50-105.00
Initial stop loss: $107.75 (R2 level)
First profit target: $100.25 (Fibonacci pivot)
Based on the provided data and current market status (Sunday night), here's the analysis for GILD's price prediction for the next trading week:
Technical Analysis
- RSI (14) at 68.44 indicates approaching overbought territory but not yet extreme
- MACD shows positive momentum with MACD (2.65) above signal line (1.85)
- Price is trading above all major moving averages (SMA 5,10,20,60,200)
- Bollinger Bands show price near upper band (BBP at 0.81), suggesting strong momentum
Recent Price Action
- Current price: $104.08
- Last week's trading range: $103.92 - $106.69
- Volume has been moderate with average daily volume around 6.4M shares
Fundamental Catalysts
- Q4 2024 results exceeded expectations with adjusted EPS of $1.90 vs $1.70 consensus
- Strong HIV segment performance with 16% sales growth to $5.45B
- Potential launch of lenacapavir for HIV PrEP in Summer 2025
- Piper Sandler raised price target to $110 with Overweight rating
Price Targets for Next Week
- Support levels: $102.63 (Friday's close), $100.25 (Fibonacci pivot)
- Resistance levels: $104.89 (R1), $107.75 (R2)
Trading Recommendation
SELL with the following rationale:
- RSI approaching overbought levels
- Price near upper Bollinger Band suggesting potential pullback
- Recent insider selling activity with CFO selling 137,676 shares
- Multiple institutional investors reducing positions last quarter
Target entry for short positions: $104.50-105.00
Initial stop loss: $107.75 (R2 level)
First profit target: $100.25 (Fibonacci pivot)